LEADER 01058nam 2200253la 450 001 9910482675303321 005 20221107143154.0 035 $a(UK-CbPIL)2090298301 035 $a(CKB)5500000000094421 035 $a(EXLCZ)995500000000094421 100 $a20210618d1591 uy | 101 0 $adan 135 $aurcn||||a|bb| 200 10$aHuad en falsk Eed Aluorlig oc forfærlig betyder, effter som den hellige Scrifft vduiser, Der it Christet Menniske skal vocte sig for, vnder sin Siæl saligheds Fortabelse$b[electronic resource] 210 $aCopenhagen $cMads Vingaard$d1591 215 $aOnline resource ([4] s.) 300 $aReproduction of original in Det Kongelige Bibliotek / The Royal Library (Copenhagen). 700 $aAnon$0815482 801 0$bUk-CbPIL 801 1$bUk-CbPIL 906 $aBOOK 912 $a9910482675303321 996 $aHuad en falsk Eed Aluorlig oc forfærlig betyder, effter som den hellige Scrifft vduiser, Der it Christet Menniske skal vocte sig for, vnder sin Siæl saligheds Fortabelse$92166359 997 $aUNINA LEADER 03606nam 22005775 450 001 9911034572803321 005 20251004130452.0 010 $a3-031-97397-6 024 7 $a10.1007/978-3-031-97397-0 035 $a(CKB)41571885300041 035 $a(MiAaPQ)EBC32334632 035 $a(Au-PeEL)EBL32334632 035 $a(DE-He213)978-3-031-97397-0 035 $a(OCoLC)1545124380 035 $a(EXLCZ)9941571885300041 100 $a20251004d2026 u| 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPraziquantel $eDiscovery and Development of an Anthelmintic Drug /$fedited by Thomas Spangenberg 205 $a1st ed. 2026. 210 1$aCham :$cSpringer Nature Switzerland :$cImprint: Springer,$d2026. 215 $a1 online resource (318 pages) 225 1 $aBiomedical and Life Sciences Series 311 08$a3-031-97396-8 327 $aChapter 1: A Brief History of the Pharmaceutical Industry -- Chapter 2: The Parasite`s Life Cycle and the Patient -- Chapter 3: The Medical Need for Patients with Schistosomiasis -- Chapter 4: From Small Molecule to Drug Product, the Chemical Journey of Praziquantel -- Chapter 5: The Molecular Drug Target of Praziquantel -- Chapter 6: In Vitro and In Vivo Activity of Praziquantel Against Schistosome Worms -- Chapter 7: In Life Behaviour of Praziquantel & Relationship Between Drug Exposure and Effect -- Chapter 8: Nonclinical safety of Praziquantel -- Chapter 9: Controlled Human Schistosoma mansoni Infection Model & Biomarkers -- Chapter 10: Clinical efficacy of Praziquantel on Schistosoma Infections -- Chapter 11: Regulators? Viewpoint -- Chapter 12: Proprietary Aspects of Praziquantel. 330 $aThis open-access book provides a comprehensive reference on the discovery and development of praziquantel. It presents the full research and development (R&D) journey of this essential anthelmintic drug, combining foundational science with practical insights. The book covers a wide range of topics, including a brief history of pharmaceutical industry, unmet medical needs, parasitic flatworm biology, and strategies for schistosomiasis control and elimination. Both human and animal health applications are addressed. Additional chapters explore chemical and manufacturing aspects, drug targets, biomarkers, toxicology, clinical efficacy, regulatory pathways, and Intellectual Property considerations. Rich illustrations, expert commentary, and clear summaries enhance the educational value of the text. Designed for students, academics, and industry professionals alike, this volume serves as a valuable addition to any scientific library. It also supports the United Nations Sustainable Development Goal 3 (Good Health and Well-being) by contributing to the global fight against schistosomiasis and other Neglected Tropical Diseases. 410 0$aBiomedical and Life Sciences Series 606 $aParasitology 606 $aPharmacology 606 $aPharmacovigilance 606 $aParasitology 606 $aPharmacology 606 $aDrug Safety and Pharmacovigilance 615 0$aParasitology. 615 0$aPharmacology. 615 0$aPharmacovigilance. 615 14$aParasitology. 615 24$aPharmacology. 615 24$aDrug Safety and Pharmacovigilance. 676 $a571.999 700 $aSpangenberg$b Thomas$01853271 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9911034572803321 996 $aPraziquantel$94449373 997 $aUNINA